Treatment strategies for patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to be heavily researched and ever-changing. Recent data has suggested that combination therapy with dexamethasone, remdesivir and baricitinib could decrease the severity and length of illness in patients with severe SARS-CoV-2. However; the data regarding the safety and side effects related to this combination therapy are limited to case reports. The purpose of this case report is to highlight a potentially life-threatening side effect of one or all medications mentioned above
Introduction: The coronavirus disease COVID-19 is considered a pandemic disease that has ...
The novel coronavirus SARS-CoV-2 can cause a severe and even fatal respiratory illness named COVID-1...
Objectives This study aims to describe the clinical outcomes of combination therapy with sarilumab a...
Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection...
Since the first cases were reported in December 2019, infection with the severe acute respiratory co...
A clinical decision report using: Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatme...
A 72-year-old male presented to the emergency department with a chief complaint of diarrhea after ha...
Key Clinical Message Although immunodeficient patients are less prone to develop Coronavirus disease...
The first case of SARS-CoV-2 (severe acute respiratory syndrome corona virus 2) was reported in Wuha...
We describe a patient with SARS-CoV-2 and severe pneumonia who required mechan...
© 2022. The Author(s).BACKGROUND: The risk of developing severe and even fatal coronavirus disease 2...
Combination of convalescent plasma therapy and repurposed drugs such as dexamethasone and remdesivir...
This article is made available for unrestricted research re-use and secondary analysis in any form o...
With the major spread of SARS-COV-2 around the world, its association with various pathologies has b...
Coronavirus disease 2019 (COVID-19) has affected over 200 million patients worldwide. COVID-19 is tr...
Introduction: The coronavirus disease COVID-19 is considered a pandemic disease that has ...
The novel coronavirus SARS-CoV-2 can cause a severe and even fatal respiratory illness named COVID-1...
Objectives This study aims to describe the clinical outcomes of combination therapy with sarilumab a...
Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection...
Since the first cases were reported in December 2019, infection with the severe acute respiratory co...
A clinical decision report using: Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatme...
A 72-year-old male presented to the emergency department with a chief complaint of diarrhea after ha...
Key Clinical Message Although immunodeficient patients are less prone to develop Coronavirus disease...
The first case of SARS-CoV-2 (severe acute respiratory syndrome corona virus 2) was reported in Wuha...
We describe a patient with SARS-CoV-2 and severe pneumonia who required mechan...
© 2022. The Author(s).BACKGROUND: The risk of developing severe and even fatal coronavirus disease 2...
Combination of convalescent plasma therapy and repurposed drugs such as dexamethasone and remdesivir...
This article is made available for unrestricted research re-use and secondary analysis in any form o...
With the major spread of SARS-COV-2 around the world, its association with various pathologies has b...
Coronavirus disease 2019 (COVID-19) has affected over 200 million patients worldwide. COVID-19 is tr...
Introduction: The coronavirus disease COVID-19 is considered a pandemic disease that has ...
The novel coronavirus SARS-CoV-2 can cause a severe and even fatal respiratory illness named COVID-1...
Objectives This study aims to describe the clinical outcomes of combination therapy with sarilumab a...